Abstract
Phenytoin is an established drug in the treatment of acute repetitive seizures and status epilepticus. One of its main advantages over benzodiazepines is the less sedative effect. However, the possibility of cardiovascular adverse effects with the intravenous use of phenytoin cause a reluctance to its usage, and this has lead to a search for safer anticonvulsant drugs. In this study, we aimed to review the studies which evaluated the safety of phenytoin with respect to cardiovascular adverse effects. The original clinical trials and case reports listed in PUBMED in English language between the years of 1946–2014 were evaluated. As the key words, “phenytoin, diphenylhydantoin, epilepsy, seizure, cardiac toxicity, asystole, arrhythmia, respiratory arrest, hypotension, death” were used. Thirty-two clinical trials and ten case reports were identified. In the case reports, a rapid infusion rate (>50 mg/min) of phenytoin appeared as the major cause of increased mortality. In contrast, no serious cardiovascular adverse effects leading to death were met in the clinical trials which applied the recommended infusion rate and dosages. An infusion rate of 50 mg/min was reported to be safe for young patients. For old patients and patients with a cardiovascular co-morbidity, a slower infusion rate was recommended with a careful follow-up of heart rhythm and blood pressure. No cardiovascular adverse effect was reported in oral phenytoin overdoses except one case with a very high serum phenytoin level and hypoalbuminemia. Phenytoin is an effective and well tolerated drug in the treatment of epilepsy. Intravenous phenytoin is safe when given at recommended infusion rates and doses.
Similar content being viewed by others
References
Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French JA, Perucca E, Tomson T (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54:551–563
Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, Holtkamp M (2010) EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 17:348–355
Zoneraich S, Zoneraich O, Siegel J (1976) Sudden death following intravenous sodium diphenylhydantoin. Am Heart J 91:375–377
Goldschlager AW, Karliner JS (1967) Ventricular standstill after intravenous diphenylhydantoin. Am Heart J 74:410–412
Russell MA, Bousvaros G (1968) Fatal results from diphenylhydantoin administered intravenously. JAMA 206:2118–2119
Unger AH, Sklaroff HJ (1967) Fatalities following intravenous use of sodium diphenylhydantoin for cardiac arrhythmias. Report of two cases. JAMA 200:335–336
Gellerman GL, Martinez C (1967) Fatal ventricular fibrillation following intravenous sodium diphenylhydantoin therapy. JAMA 200:337–338
Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N (2007) Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 16:527–532
Kellinghaus C, Berning S, Stögbauer F (2014) Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand 129:294–299
Rudis MI, Touchette DR, Swadron SP, Chiu AP, Orlinsky M (2004) Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. Ann Emerg Med 43:386–387
Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA (2010) Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 12:165–172
Aaronson PM, Belgado BS, Spillane JP, Kunisaki TA (2011) Evaluation of intramuscular fosphenytoin vs intravenous phenytoin loading in the ED. Am J Emerg Med 29:983–989
Marchetti A, Magar R, Fischer J, Sloan E, Fischer P (1996) A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx@) versus intravenous phenytoin (Dilantin@) in hospital emergency departments. Clin Ther 18:953–966
Rai A, Aggarwal A, Mittal H, Sharma S (2011) Comparative efficacy and safety of intravenous valproate and phenytoin in children. Pediatr Neurol 45:300–304
Chitsaz A, Mehvari J, Salari M, Gholami F, Najafi M-R (2013) A comparative assessment the efficacy of intravenous infusion of sodium valproate and phenytoin in the treatment of status epilepticus. Int J Prev Med 4:S216–S221
Misra UK, Kalita J, Patel R (2006) Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 67:340–342
Gilad R, Izkovitz N, Dabby R, Rapoport A, Sadeh M, Weller B, Lampl Y (2008) Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. Acta Neurol Scand 118:296–300
Kern K, Schebesch KM, Schlaier J, Hansen E, Feigl GC, Brawanski AT, Lange M (2012) Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy. J Clin Neurosci 19:99–100
Fuller KL, Wang YY, Cook MJ, Murphy MA, D’Souza WJ (2013) Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study. Epilepsia 54:45–57
Treiman DM, Meyers PD, Walton NY et al (1998) A comparison of four treatments for generalized convulsive status epilepticus. Veterans affairs status epilepticus cooperative study group. N Engl J Med 339:792–798
Esplin DW (1957) Effects of diphenylhydantoin on synaptic transmission in cat spinal cord and stellate ganglion. J Pharmacol Exp Ther 120:301–323
Francis J, Burnham WM (1992) [3H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels. Mol Pharmacol 42:1097–1103
Dill WA, Glazko AJ, Kazenko A, Wolf LM (1956) Studies on 5, 5′-diphenylhydantoin (dilantin) in animals and man. J Pharmacol Exp Ther 118:270–279
Wilder BJ, Ramsay RE (1976) Oral and intramuscular phenytoin. Clin Pharmacol Ther 19:360–364
Swadron SP, Rudis MI, Azimian K, Beringer P, Fort D, Orlinsky M (2004) A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med 11:244–252
Ratanakorn D, Kaojarern S, Phuapradit P, Mokkhavesa C (1997) Single oral loading dose of phenytoin: a pharmacokinetics study. J Neurol Sci 147:89–92
Morita DA GT (2006) Phenytoin and fosphenytoin. In: Wyllie Elaine (ed) Treat. Epilepsie, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 785–803
Craig S (2005) Phenytoin poisoning. Neurocrit Care 3:161–170
Zaccara G, Tion C, Perucca E (2014) Seminar in epileptology interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord Epileptic Disord Epileptic Disord 16:409–432
Bivins BA, Rapp RP, Griffen WO, Blouin R, Bustrack J (1978) Dopamine-phenytoin interaction. A cause of hypotension in the critically ill. Arch Surg 113:245–249
York RC, Coleridge ST (1988) Cardiopulmonary arrest following intravenous phenytoin loading. Am J Emerg Med 6:255–259
Conn RD, Kennedy JW, Blackmon JR (1967) The hemodynamic effects of diphenylhydantoin. Am Heart J 73:500–505
Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B (1978) Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology 28:874–880
Louis S, Kutt H, McDowell F (1967) The cardiocirculatory changes caused by intravenous dilantin and its solvent. Am Heart J 74:523–529
Al-Khudhairi D, Whitwam JG (1986) Autonomic reflexes and the cardiovascular effects of propylene glycol. Br J Anaesth 58:897–902
Conn RD (1965) Diphenylhydantoin sodium in cardiac arrythmias. N Engl J Med 272:277–282
Karliner JS (1967) Intravenous diphenylhydantoin sodium (Dilantin) in cardiac arrhythmias. Dis Chest 51:256–269
Rosen M, Lisak R, Rubin IL (1967) Diphenylhydantoin in cardiac arrhythmias. Am J Cardiol 20:674–678
Carducci B, Hedges JR, Beal JC, Levy RC, Martin M (1984) Emergency phenytoin loading by constant intravenous infusion. Ann Emerg Med 13:1027–1031
Donovan PJ, Cline D (1991) Phenytoin administration by constant intravenous infusion: selective rates of administration. Ann Emerg Med 20:139–142
McWilliam PK (1958) Intravenous phenytoin sodium in continuous convulsions in children. Lancet 2:1147–1149
Tiamkao S, Sawanyawisuth K, Chancharoen A (2013) The efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study. BMC Neurol 13:98
Hawcutt DB, Sampath S, Timmis A, Newland V, Newland P, Appleton R (2011) Serum phenytoin concentrations in paediatric patients following intravenous loading. Arch Dis Child 96:883–884
Piper JD, Hawcutt DB, Verghese GK, Spinty S, Newland P, Appleton R, Hey A (2014) Phenytoin dosing and serum concentrations in paediatric patients requiring 20 mg/kg intravenous loading. Arch Dis Child 99:585–586
Martinelli EF, Mühlebach SF (2003) Rapid i.v. loading with phenytoin with subsequent dose adaptation using non-steady-state serum levels and a Bayesian forecasting computer program to predict maintenance doses. J Clin Pharm Ther 28:385–393
Handley AJ (1970) Phenytoin tolerance tests. Br Med J 3:203–204
Schmidt H, Belleza J, Dougherty Lynn White JM, Robin Lammers M (1995) Adverse Effects associated with phenytoin administration. Acad Emerg Med 2:758–759
Wallis W, Kutt H, McDowell F (2001) Intravenous diphenylhydantoin in treatment of acute repetitive seizures. 1968. Neurology 57:S49–S61
Slater RM, Smith WD, Patrick J, Mawer GE, Wilcox FL, Donnai P, Richardson T, D’Souza SW, Anderton JM (1987) Phenytoin infusion in severe pre-eclampsia. Lancet 1:1417–1421
Chance JF (1991) Emergency department treatment of alcohol withdrawal seizures with phenytoin. Ann Emerg Med 20:520–522
Appleton RE, Gill A (2003) Adverse events associated with intravenous phenytoin in children: a prospective study. Seizure 12:369–372
Salem RB, Wilder BJ, Yost RL, Doering PL, Lee C (1981) Rapid infusion of phenytoin sodium loading doses. Am J Hosp Pharm 38:354–357
De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E (2002) Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 43:175–182
Lee ST, Lui TN, Chang CN, Cheng WC, Wang DJ, Heimburger RF, Lin CG (1989) Prophylactic anticonvulsants for prevention of immediate and early postcraniotomy seizures. Surg Neurol 31:361–364
Young B, Rapp RP, Norton JA, Haack D, Walsh JW (1983) Failure of prophylactically administered phenytoin to prevent post-traumatic seizures in children. Childs Brain 10:185–192
Evers ML, Izhar A, Aqil A (1997) Cardiac monitoring after phenytoin overdose. Hear Lung J Acute Crit Care 26:325–328
Curtis DL, Piibe R, Ellenhorn MJ, Wasserberger J, Ordog G (1989) Phenytoin toxicity: a review of 94 cases. Vet Hum Toxicol 31:164–165
Wyte CD, Berk WA (1991) Severe oral phenytoin overdose does not cause cardiovascular morbidity. Ann Emerg Med 20:508–512
Earnest MP, Marx JA, Drury LR (1983) Complications of intravenous phenytoin for acute treatment of seizures. Recommendations for usage. JAMA 249:762–765
DeToledo JC, Lowe MR, Rabinstein A, Villaviza N (2001) Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin. Epilepsia 42:288
Randazzo DN, Ciccone A, Schweitzer P, Winters SL (1995) Complete atrioventricular block with ventricular asystole following infusion of intravenous phenytoin. J Electrocardiol 28:157–159
Berry JM, Kowalski A, Fletcher SA (1999) Sudden asystole during craniotomy: unrecognized phenytoin toxicity. J Neurosurg Anesthesiol 11:42–45
Lu C-H, Su C-M, Kung C-T, Wang Y-C (2009) Life-threatening cardiotoxicity due to chronic oral phenytoin overdose. Neurol India 57:200
Gugler R, Manion CV, Azarnoff DL (1976) Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther 19:135–142
Meek PD, Davis SN, Collins DM, Gidal BE (2015) Guidelines for nonemergency use of parenteral phenytoin products. Arc Intern Med 159:2639–2644
Binder L, Trujillo J, Parker D, Guetter A (1996) Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters. Am J Emerg Med 14:398–401
Prasad K, Al-Roomi K, Krishnan PR, Sequeira R (2005) Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev. doi:10.1002/14651858.CD003723
Siebert WJ, McGavigan AD (2013) Requirement for cardiac telemetry during intravenous phenytoin infusion: guideline fact or guideline fiction? Intern Med J 43:7–17
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Rights and permissions
About this article
Cite this article
Guldiken, B., Rémi, J. & Noachtar, S. Cardiovascular adverse effects of phenytoin. J Neurol 263, 861–870 (2016). https://doi.org/10.1007/s00415-015-7967-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-015-7967-1